Stay updated on Durvalumab vs Placebo in Early NSCLC Clinical Trial
Sign up to get notified when there's something new on the Durvalumab vs Placebo in Early NSCLC Clinical Trial page.

Latest updates to the Durvalumab vs Placebo in Early NSCLC Clinical Trial page
- Check7 days agoChange DetectedNew history entries document additional study record updates (e.g., recruitment status and contacts/locations) on the Record History page. The overall page layout remains unchanged.SummaryDifference0.1%

- Check14 days agoNo Change Detected
- Check35 days agoChange DetectedAdded a government operating-status notice and a new version tag (v3.2.0); removed the old version tag (v3.1.0).SummaryDifference9%

- Check43 days agoChange DetectedUpdated the page revision from v3.0.2 to v3.1.0, indicating a new software release or document update. No changes to core content, pricing, or stock are evident.SummaryDifference0.2%

- Check57 days agoChange DetectedVersion updated from v3.0.1 to v3.0.2, and the Back to Top element was removed. No other substantive content changes.SummaryDifference0.5%

- Check64 days agoChange DetectedThe web page has been updated from version 3.0.0 to version 3.0.1, indicating a revision in the content. Additionally, a 'Back to Top' feature has been added for improved navigation.SummaryDifference0.5%

- Check71 days agoChange DetectedThe web page has undergone significant updates, including the addition of a facility name and location details, while removing specific state, country, and city information. This suggests a shift towards a more generalized presentation of study locations.SummaryDifference49%

Stay in the know with updates to Durvalumab vs Placebo in Early NSCLC Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Durvalumab vs Placebo in Early NSCLC Clinical Trial page.